| Expression pattern: |
DN |
| Associated gene: |
DIDO1-529aa, PARP1, PRDX2, RBX1 |
| Associated microRNA: |
- |
| Biological function: |
Inhibits GC cell proliferation, migration and invasion; promotes apoptosis; suppresses tumor growth and metastasis in vivo. |
| Molecular mechanism: |
Encodes DIDO1-529aa that interacts with PARP1 and inhibits its activity; binds PRDX2 and promotes RBX1-mediated ubiquitination/proteasomal degradation of PRDX2, inactivating downstream pathways (Wnt/beta-catenin, MAPK, PI3K/Akt). |
| Biological pathway or process: |
proliferation (inhibits); migration (inhibits); invasion (inhibits); apoptosis (promotes); metastasis (inhibits); EMT (inhibits); Wnt/beta-catenin (inhibits); MAPK (inhibits); PI3K/AKT (inhibits); ubiquitination (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; Bioinformatics Analysis; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; FISH / smFISH; Clinical Sample Validation; Survival Analysis; Transfection; CCK8; Colony Formation Assay; Transwell Assay; Annexin V/PI Flow Cytometry; In Vivo Animal Model; IHC (Immunohistochemistry); TUNEL; RNA Pull-Down; Western Blot; Co-IP; IF (Immunofluorescence); RNA-seq |
| Clinical significance: |
Low circDIDO1 levels are associated with larger tumor size, distant metastasis and shorter overall survival; downregulation predicts poor prognosis and may serve as a prognostic biomarker/therapeutic target. |
| Description: |
circDIDO1 (hsa_circ_0061137), derived from DIDO1, is down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting proliferation, migration/invasion and metastasis while promoting apoptosis. It functions through dual mechanisms: encoding a DIDO1-529aa peptide that binds PARP1 to inhibit its activity, and binding PRDX2 to promote RBX1-mediated ubiquitination and proteasomal degradation, leading to inactivation of Wnt/beta-catenin, MAPK and PI3K/AKT signaling. |
| Confidence score: |
0.8793 |